Why American Bitcoin (ABTC) Stock Is Sliding Friday
Shares of American Bitcoin are trading lower Friday, pulling back from Thursday’s rally amid digital-asset weakness after labor market data.
Stocks · News reference
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of software companies are trading lower after August's hotter-than-expected payrolls report increased expectations that the Federal Reserve could raise interest rates at its next meeting. A stronger U.S. dollar and higher rate expectations are weighing on growth stocks by reducing investor appetite for higher-risk assets.
Shares of crypto-related companies are trading lower amid a decline in Bitcoin prices following August's hotter-than-expected payrolls report, which boosted expectations for a potential Federal Reserve rate hike at its next meeting. A stronger U.S. dollar and higher interest-rate expectations are further weighing on crypto and other risk assets by reducing investor appetite for speculative investments.
Eric Trump Says Our Mission Hasn't Changed as American Bitcoin Marks One Year of Going Public, but ABTC Stock Got Battered
Eric Trump celebrated on Thursday, Sept. 3, the first anniversary of American Bitcoin Corp. going public, reiterating the vision of making the U.S. a leader in the Bitcoin economy.
Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M
Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales
Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
First-in-class pan-RAS(ON) ADC is cleared for clinical developmentDesigned to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.IND submissions to U.S. FDA and China NMPA are in